The pharmaceutical industry is on the brink of significant transformation, driven by advancements in oncology, artificial intelligence (AI), and evolving policy landscapes. As we look towards 2025 and beyond, these changes promise to revolutionize drug development, clinical trials, and patient
Artificial intelligence (AI) is revolutionizing various sectors, and medicine is no exception. Researchers at UC San Francisco (UCSF) are at the forefront of integrating AI and machine learning with medical imaging to create human-centered AI solutions. These innovations aim to tackle some of the
NEC Corporation and Biomy, Inc. have announced a groundbreaking partnership aimed at revolutionizing digital pathology through the integration of artificial intelligence (AI) and deep learning (DL). This collaboration, formalized in a recent Memorandum of Understanding (MoU), seeks to enhance
Artificial intelligence (AI) has garnered significant attention in recent years, particularly within the medical field for its potential to revolutionize various aspects of healthcare. The integration of AI in breast cancer detection promises not only an increase in accuracy but also a potential
Stanford Medicine researchers have recently introduced an innovative artificial intelligence (AI) model named MUSK (multimodal transformer with unified mask modeling) that significantly improves the accuracy of cancer prognosis predictions. By integrating both visual and textual medical data, this
The potential application of GPT-4, a large language model (LLM), in simplifying diabetes management by accurately interpreting continuous glucose monitoring (CGM) data and generating actionable insights is a promising development in healthcare. Researchers have been exploring innovative ways to
